Caroline Chung1, Brandon Driscoll1, Warren Foltz1, Cynthia Menard1, David Jaffray1, and Catherine Coolens1
Our preclinical study of sunitinib (SU) in combination with conformal large single fraction radiation in an orthotopic murine brain tumor model, discovered that changes in apparent diffusion coefficient (ADC), AUC and Ktrans were promising imaging biomarkers that could predict response to SU as well as combined SU and radiation. Based on our preclinical findings, we designed a prospective phase I trial of SU and radiosurgery (SRS) for brain metastases that incorporated translational investigation of these imaging biomarkers. Here we summarize our discovery of differential ADC and AUC responses to sunitinib between renal cell cancer and other histology brain metastases.
